Hongmei Xu

Company: Bicycle Therapeutics

Job title: Vice President, Head of Quantitative Pharmacology

Seminars:

Surrogate Endpoints in Oncology Dose Optimization Strategy 11:00 am

Challenges in dose optimization for oncology narrow therapeutic index compounds What surrogate endpoints might be helpful for dose optimization when look at early (less mature) efficacy and safety data?Read more

day: Conference Day One

Roundtable Discussion: Subcutaneous vs. UV Dosing: Different Approaches Required for Changing Dosing from a Clinician’s Perspective 1:00 pm

Comparing the patient experience and practical considerations of switching from IV to subcutaneous dosing Understanding how route of administration impacts PK, tolerability, and trial design decisions Exploring what it takes to make the transition between dosing routes work for patients and studiesRead more

day: Conference Day One

Investigating the Effects on Modelling & Dosing When Expanding into ADC Combinations 9:30 am - 12:30 pm

Join this workshop to explore how next generation dosing strategies can unlock the full potential of ADC combination therapies. There is no silver bullet for treatment, and combinations are widely considered the next step in oncology treatment, so in this workshop you’ll dive into the latest thinking, tools, and translational tactics that are reshaping combination…Read more

day: Pre-Conference Workshop Day